22245-98-3

Usage

Uses

Used in Pharmaceutical Industry:
6-HYDROXY-3,4-DIHYDRO-1(2H)-ISOQUINOLINONE is used as a potential therapeutic agent for various applications due to its pharmacological properties.
1. As an Antioxidant:
6-HYDROXY-3,4-DIHYDRO-1(2H)-ISOQUINOLINONE is used as an antioxidant agent for its ability to neutralize free radicals and protect cells from oxidative damage, which may contribute to the prevention and treatment of various diseases.
2. As an Anti-Inflammatory Agent:
6-HYDROXY-3,4-DIHYDRO-1(2H)-ISOQUINOLINONE is used as an anti-inflammatory agent for its potential to reduce inflammation and alleviate symptoms associated with inflammatory conditions.
3. In Neurological Disorder Treatment:
6-HYDROXY-3,4-DIHYDRO-1(2H)-ISOQUINOLINONE is used as a potential therapeutic agent for neurological disorders, given its potential to modulate neuroprotective pathways and improve cognitive function.
4. In Cardiovascular Disease Treatment:
6-HYDROXY-3,4-DIHYDRO-1(2H)-ISOQUINOLINONE is used as a potential therapeutic agent for cardiovascular diseases, as it may help improve blood flow, reduce oxidative stress, and protect the heart from damage.
5. In Drug Design and Development:
6-HYDROXY-3,4-DIHYDRO-1(2H)-ISOQUINOLINONE is used as a chemical scaffold for the design and development of new pharmaceutical drugs, leveraging its pharmacological properties to create novel therapeutic agents for various diseases.
Further research is needed to fully understand the effects and potential uses of 6-HYDROXY-3,4-DIHYDRO-1(2H)-ISOQUINOLINONE, as well as to optimize its therapeutic potential and safety profile.

InChI:InChI=1/C9H9NO2/c11-7-1-2-8-6(5-7)3-4-10-9(8)12/h1-2,5,11H,3-4H2,(H,10,12)

Upstream product

• 22246-12-4 6-methoxy-1,2,3,4-tetrahydro-1-oxoisoquinoline 
• 3470-49-3 5-hydroxy-2,3-dihydro-1H-indene-1-one 
• 588-05-6 m-tyramine 
• 110192-21-7 N-(methoxycarbonyl)-2-(3'-methoxyphenyl)ethylamine 
• 76-03-9 trichloroacetic acid 
• 5111-70-6 5-methoxy-1-indanone 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 33543-63-4 ethyl-N-<2-(3-methoxyphenyl)ethyl>-carbamate 

Downstream Products

• 1203952-92-4 6-{5-[1-methyl-1-(2,4,6-trifluorophenoxy)ethyl]-1,3,4-oxadiazol-2-yl}-3,4-dihydroisoquinolin-1(2H)-one 
• 1363047-10-2 5-(1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yloxy)picolinonitrile 
• 14446-24-3 6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 1363047-03-3 4-(1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yloxy)benzonitrile 
• 1388766-13-9 4-(1-oxo-2-(2-oxoethyl)-1,2,3,4-tetrahydroisoquinolin-6-yloxy)benzonitrile 
• 1388766-50-4 4-(2-allyl-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yloxy)benzonitrile 
• 1131216-22-2 4-[(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy]benzonitrile hydrochloride 

Relevant academic research and scientific papers

1-[2-(1-Cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one: a Histamine H3 Receptor Inverse Agonist with Efficacy in Animal Models of Cognition

A series of chemical optimizations, which was guided by in vitro affinity at histamine H3 receptor (H3R), modulation of lipophilicity, ADME properties and preclinical efficacy resulted in the identification of 1-[2-(1-cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one (45 e) as a potent and selective (Ki=4.0 nM) H3R inverse agonist. Dipsogenia induced by (R)-α-methylhistamine was dose dependently antagonized by 45 e, confirming its functional antagonism at H3R. It is devoid of hERG and phospholipidosis issues. Compound 45 e has adequate oral exposures and favorable half-life in both rats and dogs. It has demonstrated high receptor occupancy (ED80=0.22 mg/kg) and robust efficacy in object recognition task and, dose dependently increased acetylcholine levels in brain. The sub-therapeutic doses of 45 e in combination with donepezil significantly increased acetylcholine levels. The potent affinity, selectivity, in vivo efficacy and drug like properties together with safety, warrant for further development of this molecule for potential treatment of cognitive disorders associated with Alzheimer's disease.

FLUOROALLYLAMINE DERIVATIVE AND USE THEREOF

The present invention relates to a fluoroallylamine derivative and use thereof. In particular, the present invention relates to a compound as shown in Formula I, a prodrug, an isomer, an isotope-labeled compound, a solvate or a pharmaceutically acceptable salt thereof, which has VAP-1/SSAO inhibitory activity, and can be used for treating a disease associated with VAP-1/SSAO overactivity.

Discovery of 5-phenoxy-2-aminopyridine derivatives as potent and selective irreversible inhibitors of bruton’s tyrosine kinase

As a member of the tyrosine protein kinase Tec (TEC) family, Bruton’s tyrosine kinase (BTK) is considered a promising therapeutic target due to its crucial roles in the B cell receptor (BCR) signaling pathway. Although many types of BTK inhibitors have been reported, there is an unmet need to achieve selective BTK inhibitors to reduce side effects. To obtain BTK selectivity and efficacy, we designed a novel series of type II BTK inhibitors which can occupy the allosteric pocket induced by the DFG-out conformation and introduced an electrophilic warhead for targeting Cys481. In this article, we have described the structure-activity relationships (SARs) leading to a novel series of potent and selective piperazine and tetrahydroisoquinoline linked 5-phenoxy-2-aminopyridine irreversible inhibitors of BTK. Compound 18g showed good potency and selectivity, and its biological activity was evaluated in hematological tumor cell lines. The in vivo efficacy of 18g was also tested in a Raji xenograft mouse model, and it significantly reduced tumor size, with 46.8% inhibition compared with vehicle. Therefore, we have presented the novel, potent, and selective irreversible inhibitor 18g as a type II BTK inhibitor.

Quinoline and Isoquinoline Based HDAC Inhibitors and Methods of Use Thereof

The present invention relates to methods of modulating activity of histone deacetylases (HDACs). The present invention also relates to methods of treating HDAC-associated diseases including, but not limited to, cancers, inflammatory disorders, and neurode

Halogenated allyl amine type SSAO/VAP-1 inhibitor and application thereof

The invention belongs to the technical field of medicine, and particularly relates to a halogenated allyl amine type compound shown as a formula I, medically acceptable salt, ester or stereo isomers thereof, wherein R1, R2, R3, R4, R5, R6, L1, Cy1, R7 and p are defined in description. The invention also relates to a medicine preparation containing the compounds, a medicine composition containing the compounds, and application of the compounds to prevention and/or treatment on diseases relevant to SSAO/VAP 1 protein or diseases caused by SSAO/VAP 1 protein mediating. The formula I is shown in the description.

Light-Driven Intramolecular C?N Cross-Coupling via a Long-Lived Photoactive Photoisomer Complex

Reported herein is a visible-light-driven intramolecular C?N cross-coupling reaction under mild reaction conditions (metal- and photocatalyst-free, at room temperature) via a long-lived photoactive photoisomer complex. This strategy was used to rapidly prepare the N-substituted polycyclic quinazolinone derivatives with a broad substrate scope (>50 examples) and further exploited to synthesize the natural products tryptanthrin, rutaecarpine, and their analogues. The success of gram-scale synthesis and solar-driven transformation, as well as promising tumor-suppressing biological activity, proves the potential of this strategy for practical applications. Mechanistic investigations, including control experiments, DFT calculations, UV-vis spectroscopy, EPR, and X-ray single-crystal structure of the key intermediate, provides insight into the mechanism.

Quantum Dot Based Luminescent Nanoprobes for Sigma-2 Receptor Imaging

The increasing importance of sigma-2 receptor as target for the diagnosis and therapy of tumors paves the way for the development of innovative optically traceable fluorescent probes as tumor cell contrast and therapeutic agents. Here, a novel hybrid organic-inorganic nanostructure is developed by combining the superior fluorescent properties of inorganic quantum dots (QDs), coated with a hydrophilic silica shell (QD@SiO2 NPs), the versatility of the silica shell, and the high selectivity for sigma-2 receptor of the two synthetic ligands, namely, the 6-[(6-aminohexyl)oxy]-2-(3-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)propyl)-3,4-dihydroisoquinolin-1(2H)-one (MLP66) and 6-[1-[3-(4-cyclohexylpiperazin-1-yl)propyl]-1,2,3,4-tetrahydronaphthalen-5-yloxy]hexylamine (TA6). The proposed nanostructures represent a challenging alternative to all previously studied organic small fluorescent molecules, based on the same sigma-2 receptor affinity moieties. Flow cytometry and confocal fluorescence microscopy experiments, respectively, on fixed and living cancerous MCF7 cells, which overexpress the sigma-2 receptor, prove the ability of functionalized (QD@SiO2-TA6 and QD@SiO2-MLP66) NPs to be internalized and demonstrate their affinity to the sigma-2 receptor, ultimately validating the targeting properties conveyed to the NPs by sigma-2 ligand conjugation. The presented QD-based nanoprobes possess a great potential as in vitro selective sigma-2 receptor imaging agent and, consequently, could provide a significant impact to future theranostic applications.

1,2,3,4-TETRAHYDROISOQUINOLINE COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR ANTAGONISTS AND DEGRADERS

The present invention relates to compounds of formula (I) in which n, R1, R2, R3, R4and R5 are as defined in the claims; capable of being both potent antagonists and degraders of estrogen receptors. Also described is a process for the preparation of compounds of the invention, and the invention further provides pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.

2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists

On the basis of the previously reported benzimidazole 1,3′- bipyrrolidine benzamides (1), a new class of 2-(pyrrolidin-1-yl)ethyl-3,4- dihydroisoquinolin-1(2H)-one derivatives (3-50) were synthesized and evaluated as potent H3 receptor antagonists. In particular, compound 39 exhibited potent in vitro binding and functional activities at the H3 receptor, good selectivities against other neurotransmitter receptors and ion channels, acceptable pharmacokinetic properties, and a favorable in vivo profile.

Design, synthesis, and structure-activity relationship studies of conformationally restricted mutilin 14-carbamates

We report herein the design, synthesis, and structure-activity relationship studies of conformationally restricted mutilin 14-carbamates based on the structure of SB-222734. The antibacterial activities of these newly synthesized compounds were also evaluated and compared with linezolid and retapamulin. Results showed that most of the target compounds exhibit good potency in inhibiting the growth of Gram-positive bacteria including Methicillin- susceptible Staphylococcus aureus MSSA (MIC: 0.0625-2 μg/mL), Methicillin-resistant S. aureus MRSA (MIC: 0.0625-2 μg/mL), Methicillin-susceptible Staphylococcus epidermidis MSSE (MIC: 0.0625-2 μg/mL), Methicillin-resistant S. epidermidis MRSE (MIC: 0.0625-2 μg/mL), and Streptococcus pneumonia (MIC: 0.0625-4 μg/mL). In particular, three remarkable compounds of this series (12l, 12m, and 21l) exhibited comparable in vitro antibacterial profiles to that of retapamulin.